Navigation Links
Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
Date:11/27/2007

SOUTH SAN FRANCISCO, Calif., Nov. 27 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the development of monoclonal antibody therapeutics (MAbs) for cancer, today announced it is continuing to enroll new patients in the maximum tolerated dose cohort expansion segment of its Phase 1/2a trial for patients with cancers of the gastrointestinal tract that express the RAAG12 antigen.

RAAG12 is a glycotope (sugar structure) that is widely found on the surface of tumor cells of many kinds of cancer, particularly cancers of the gastrointestinal tract (adenocarcinomas of gastroesophageal, pancreatic and colorectal origin). RAV12, Raven's lead clinical monoclonal antibody drug candidate, targets the RAAG12 antigen.

This segment of the trial will yield additional information about the safety of the drug and define the pharmacokinetics of the antibody.

The appropriate dose and schedule of RAV12 was chosen in a dose-escalation segment of the Phase 1/2a trial that involved 33 patients. This trial revealed that a fractionated dosing regimen provided an improved safety profile for the antibody. Raven is now enrolling patients in a second segment of the trial in which all patients are receiving the recommended dose and schedule of drug. Information from the Phase 1/2a trial will be supporting the dosing in a Phase 2 study in pancreatic cancer, the next clinical trial scheduled for RAV12.

The trial is being conducted at five institutions in the United States: The Sarah Cannon Cancer Center in Nashville, TN; The Fox Chase Cancer Center in Philadelphia, PA; Premiere Oncology in Santa Monica, CA; Georgetown University Medical Center in Washington, DC; and The University of Miami Medical Center in Miami, FL.

About RAV12

RAV12 is a novel, chimeric monoclonal antibody that is directed against a primate-specific glycotope (sugar structure) that is widely displayed on the surfaces of tumor cells, particularly tho
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Steven Rash , the CEO of Algae International Group, ... Seed & Oil Company, presented the Company,s latest developments ... York City.  Mr. Rash,s presentation featured the Company,s Product ... Company has recently announced the Dube Hemp Energy ... the EpiVape , and Hempster Clothing .  ...
(Date:4/17/2015)... Research and Markets ( http://www.researchandmarkets.com/research/256szd/corporate ) ... of Pharma in 2014 - a Perspective of Mental ... their offering. For the first time, in ... reputation of the pharmaceutical industry held by patient groups ... of patient organisations representing all therapy areas. ...
(Date:4/16/2015)... , April 16, 2015 Mindray Medical ... manufacturer, and marketer of medical devices worldwide, announced ... and Exchange Commission an Annual Report on Form 20-F ... ended December 31, 2014. An electronic version of Mindray,s ... Mindray,s investor relations website at  http://ir.mindray.com  or  http://www.sec.gov ...
Breaking Medicine Technology:American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission 2
... Inc. (NYSE: LDR ) announced today that ... of $0.5375 per share for the fourth quarter of fiscal ... to shareholders of record on September 11, 2010. ... leading provider of technical and analytical services to determine occupational ...
... OREX ), a biopharmaceutical company focused on the ... the Compensation Committee of the Company,s Board of Directors approved ... of 10,000 shares of common stock to two new employees. ... be incentive stock options to the extent permitted by law ...
Cached Medicine Technology:Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 2
(Date:4/18/2015)... YORK (PRWEB) April 18, 2015 Review ... are hosting a ‘Strategies for Success’ program for cataract ... Surgeons meeting in San Diego, where eye surgeon Jeffrey ... for this invitation-only event. Dr. Martin is the Managing ... Review of Ophthalmology chose Dr. Martin to lead this ...
(Date:4/18/2015)... 2015 Lowcostcarinsuranceprice.com has released a new ... on auto insurance prices . , Drivers ... vehicle theft may have to pay more for auto ... insurance policies can also offer protection against vehicle theft. ... compared online on a single website: http://lowcostcarinsuranceprice.com/ ...
(Date:4/18/2015)... 2015 Patients who undergo radiation for ... later in life, but the disease is likely to ... unrelated to radiation. Surviving Mesothelioma has just posted the ... Click here to read it now. , Scientists ... of 45 patients who had both a hematologic cancer ...
(Date:4/18/2015)... In the past few weeks, TheBeautyPlace.com ... , "We had to run maintenance on our shipping ... Jennifer Ramirez, the PR Director. "It disrupted our regular ... we are back on track after having completed the ... changing phone systems which has not allowed some calls ...
(Date:4/18/2015)... 18, 2015 On April 14th, 2015, Symantec ... , which they say, “exposes a tactical shift by cyberattackers.” ... variants were introduced in 2014 - almost a million a ... threats to be identified and patched by prominent manufacturers – ... that doing business in a digital world can be fraught ...
Breaking Medicine News(10 mins):Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:High Rates Of Car Theft Can Have An Impact on Auto Insurance Prices! 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Temporary Number Available 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5
... children fail to reach their full potential because they ... care, according to new research funded by the Economic ... disabled children often experience discrimination, exclusion and even violence," ... implemented the study at the Manchester Metropolitan University. "The ...
... HealthDay Reporter , THURSDAY, Dec. 1 (HealthDay News) ... issued new guidelines aimed at helping speed up the ... a reality, such technologies could make a huge difference ... injections to control their blood sugar and survive. ...
... candidates want to be involved in decisions regarding quality ... accept organs with a higher risk of failure, according ... than 42 percent of patients would choose to remain ... quality" liver according to the study,s lead author Michael ...
... THURSDAY, Dec. 1 (HealthDay News) -- ,The timing of an ... death, a new study finds. For example, there,s no ... afternoon versus the morning or on Monday instead of Friday, ... that fatigue may lead to a higher rate of safety ...
... likely to stick to prescribed treatment when a partner ... a team of sleep researchers. Obstructive sleep apnea occurs ... the most common type of sleep-disordered breathing, and chances ... The first line of treatment for sleep apnea is ...
... , THURSDAY, Dec. 1 (HealthDay News) -- Optimism ... marks for males, a new study suggests. Researchers at ... and grades of 174 business undergraduates (28 percent male, 72 ... that female students who were more optimistic had higher grades ...
Cached Medicine News:Health News:Disabled children do matter 2Health News:Disabled children do matter 3Health News:FDA Moves to Speed Development of Artificial Pancreas Systems 2Health News:FDA Moves to Speed Development of Artificial Pancreas Systems 3Health News:Transplant candidates seek best quality livers, even if it means waiting longer 2Health News:Time of Surgery Doesn't Influence Results, Study Says 2Health News:Innovative approaches help sleep apnea sufferers benefit from CPAP 2
The Horizontal-Vertical (H/V) lumbar valve system is the only differential pressure valve for lumbo-peritoneal shunting, which addresses orthostatic overdrainage....
26 cm - 10 1/4, 140 mm - 5 1/2, bayonet-shaped, flexible, 90 angle, 4 mm...
Toothed pituitary rongeur. Straight....
Micro pituitary style scissors, alligator action, semi-malleable shaft. Curved right....
Medicine Products: